scholarly journals Rapid improvement of respiratory quality in asthmatic children after "assisted drainage" therapy

2010 ◽  
Vol 50 (4) ◽  
pp. 199
Author(s):  
Haryono Utomo ◽  
Ariyanto Harsono
Keyword(s):  
Asthma Management ◽  
Persistent Asthma ◽  
Forced Expiratory Volume ◽  
Rapid Improvement ◽  
Test Analysis ◽  
Asthmatic Children ◽  
Focal Infection ◽  
Dental Practitioners ◽  
Asthma Patients ◽  
Mild Persistent Asthma

Background  Whilst current asthma management is well-developed, there are still 5-10% uncontrolled asthma patients with unknown etiologies. However, its connection with oral focal infection is still uncertain. Therefore, a collaborated research for asthma management was conducted by pediatricians and dental practitioners. Within minutes after the "assisted drainage" therapy, a modification of healing root planning procedure, there is rapid improvement of respiratory function, ie., forced expiratory-volume one second (FEV1) in asthmatic children. This quick response usually achieved by oral inhalation.Objective To investigate the effectiveness of the assisted drainage therapy in the improvement of respiratory quality.Methods Fifteen asthmatic children were subjected to a longitudinal study for two weeks. In tbe first week they were instructed for al lergen avoidance only and the fOllowing one week was combined with tbe assisted drainage therapy, followed by  mental health education and dental plaque control therapy. Each s'ubject was af'sef'sed for respiratory quality with a computerized spirometer and blood sampling test. Paired t-test analysis was used for statistical analysis.Results Assisted drainage therapy was performed, within minutes FEV1 increased significantly (P= 0.001). Additionally, there were significant differences serum histamine (P= 0,001) pre and post treatment.Conclusions The assisted drainage therapy is effective as an adjuvant therapy for mild persistent asthma in children.

Inhaled Budesonide vis-à-vis Inhaled Mometasone in Chinese Children with Mild Persistent Asthma: A Single-Center, Retrospective Study

Pharmacology ◽  
2021 ◽  
pp. 1-7
Author(s):  
Pei Gao ◽  
Ying Ding ◽  
Bingru Yin ◽  
Haoxiang Gu
Keyword(s):  
Retrospective Study ◽  
Asthma Exacerbation ◽  
Inhaled Corticosteroids ◽  
Persistent Asthma ◽  
Forced Expiratory Volume ◽  
Single Center ◽  
Level Of Evidence ◽  
Asthmatic Children ◽  
Technical Efficacy ◽  
Mild Persistent Asthma

<b><i>Introduction:</i></b> A very limited option of inhaled corticosteroids (ICSs) is approved for pediatric use in China because in children the use of ICSs for long periods is associated with dose-dependent growth reduction. Due to the lack of consensus on which is the best ICS-based treatment option to manage mild persistent asthma in children, the present study was performed to evaluate the efficacy and safety of budesonide (BUD)-based therapy vis-à-vis mometasone-based therapy in children with mild persistent asthma. <b><i>Methods:</i></b> A single-center, retrospective study was conducted in asthmatic children aged between 6 and 11 years. BUD and mometasone furoate (MF) were administered as per the approved dosing regimen using pressurized metered-dose inhalers via oral inhalation route for a period of 12 weeks. The study outcome was assessed in terms of the forced expiratory volume in 1 s (FEV<sub>1</sub>), symptom scores, and nonoccurrence of side effects. <b><i>Results:</i></b> Among the 77 asthmatic children, 71 completed the study treatment and were used in carrying out the analysis. The improvement of spirometric parameters like FEV<sub>1</sub>, Tiffeneau-Pinelli index (FEV1/forced vital capacity [FVC]), and peak expiratory flow (PEF) values observed in the MF cohort was significantly greater than those of the BUD cohort (<i>p</i> &#x3c; 0.05 for all). An increase of approximately 12%/child was observed for FEV<sub>1</sub>/FVC ratios for the BUD cohort and MF cohorts. After the 12-week study, the PEF<sub>m</sub> and PEF<sub>e</sub> values increased to about 50 L/min/child for the BUD cohort and about 98 L/min/child for the MF cohort. During the study, no asthma exacerbation event was observed in the MF cohort, whereas 1 child in the BUD cohort had asthma exacerbation in week 4. The use of rescue medication during the study was required for 16.2 and 6% of children, respectively, for BUD and MF cohorts. Owing to low dosing frequency, MF could provide a better treatment approach than BUD due to improved patient compliance. <b><i>Conclusions:</i></b> Although both drugs showed improvement in the quality of life of asthmatic children with manageable treatment-emergent adverse effects, the improvement was augmented in MF-treated children. <b><i>Level of Evidence:</i></b> The level of evidence was III. <b><i>Technical Efficacy Stage:</i></b> The technical efficacy stage was 4.

scholarly journals Serum Eosinophilic cationic protein (ECP) as an effective biological marker to monitor therapy in bronchial asthma patients.

2011 ◽  
Vol 5 (1) ◽  
pp. 3-7 ◽  
Author(s):  
Afroza Begum ◽  
Humayun Sattar ◽  
Abu Naser Ibne Sattar ◽  
Md. Ruhul Amin Miah ◽  
Ahmed Abu Saleh
Keyword(s):  
Bronchial Asthma ◽  
Persistent Asthma ◽  
Biological Marker ◽  
Forced Expiratory Volume ◽  
Asthma Therapy ◽  
Eosinophilic Cationic Protein ◽  
Cationic Protein ◽  
Before And After ◽  
Asthma Patients

Clinically diagnosed bronchial asthma patients comprising of new cases, on therapy or follow up were enrolled for this study to see if the new biological marker Eosinophilic cationic protein (ECP) can be used as a more precise marker to monitor therapy than the presently used conventional ones like FEV1% predicted, PEFR, and Circulating eosinophil (C.E) count. Out of 70 bronchial asthma patients, 30 intermittent, 4 mild persistent, 24 moderate persistent and 12 severe persistent asthma patients were included, while 45 cases were enrolled for follow up. Serum level of eosinophil granular protein, Eosinophilic cationic protein (ECP) was measured in relation to changes in their forced expiratory volume in 1st second (FEV1% predicted) and Circulating Eosinophil count (%) before and after therapy in 45 follow up patients on asthma therapy. In this study, it was observed that C.E count (%) and FEV1% predicted were not decreased significantly and serum eosinophilic cationic protein (ECP) decreased significantly (p<0.001) after asthma therapy. Thus, serum ECP level can be used as a biological marker than other conventionally used marker (FEV1, C.E count) to monitor therapeutic efficacy in bronchial asthma patients.DOI: http://dx.doi.org/10.3329/bjmm.v5i1.15813 Bangladesh J Med Microbiol 2011; 05 (01): 3-7

scholarly journals Assessment of Asthma Control and Severity among Children According to Global Initiative for Asthma Guidelines in Sulaimani City-Iraq

2016 ◽  
Vol 12 (3) ◽  
pp. 160
Author(s):  
Adnan M. H. Hamawandi ◽  
Kosar M Ali ◽  
Ali Z. Naji
Keyword(s):  
Asthma Control ◽  
Objective Assessment ◽  
Asthma Management ◽  
Persistent Asthma ◽  
Cross Sectional ◽  
Asthmatic Children ◽  
Global Initiative For Asthma ◽  
Severe Persistent Asthma ◽  
Global Initiative ◽  
Gina Guidelines

Background: Asthma is a common and potentially serious chronic disease that imposes a substantial burden on patients, their families and the community. Objective: Assessment of the level of asthma control and severity in asthmatic children in Sulaimani city according to the global initiative for asthma (GINA) guidelines. Methods: A cross-sectional study of 82 patients who are known cases of asthma, aged 5 – 15 years , from 1st of March 2014 to 1st of August 2014. Results: Out of 82 patients in our study, 20.8%were classified as having intermittent asthma all of them have well controlled asthma, 42.7% of those classified as having mild persistent asthma 65.7% of them have well controlled asthma, 26.8% of those classified as having moderate persistent asthma 54.5% of them have partly controlled asthma, and 9.8%of those classified as having severe persistent asthma the majority of them 87.5% have uncontrolled asthma and none of them reached to the controlled asthma level according to GINA guidelines. Regarding the peak expiratory flow (PFT) we notice that 58.8% of asthmatic children who were classified as having intermittent severity, their PEF measurements ranged between 160- 250 l/min while those with severe persistent asthma 75% of them have readings between 50-150 l/min. Conclusion: Current levels of asthma control in the Sulaimani city fall far short of the goals specified in the GINA guidelines for asthma management. Also there is a strong correlation between PEF measurements and the level of asthma severity,

scholarly journals PAA9 RISK-ADJUSTED COSTS AND OUTCOMES FOR MILD PERSISTENT ASTHMA PATIENTS ON ALTERNATIVE CONTROLLER THERAPIES

2007 ◽  
Vol 10 (6) ◽  
pp. A400
Author(s):  
G Colice ◽  
AP Yu ◽  
JL Ivanova ◽  
M Hsieh ◽  
HG Birnbaum ◽  
...  
Keyword(s):  
Persistent Asthma ◽  
Asthma Patients ◽  
Mild Persistent Asthma

Costs and Resource Use of Mild Persistent Asthma Patients Initiated on Controller Therapy

2008 ◽  
Vol 45 (4) ◽  
pp. 293-299 ◽  
Author(s):  
Gene L. Colice ◽  
Andrew P. Yu ◽  
Jasmina I. Ivanova ◽  
Matthew Hsieh ◽  
Howard G. Birnbaum ◽  
...  
Keyword(s):  
Resource Use ◽  
Persistent Asthma ◽  
Asthma Patients ◽  
Mild Persistent Asthma

Comparison of montelukast versus montelukast plus inhaled corticosteroid (Budesonide) in children with mild persistent asthma.

2021 ◽  
Vol 28 (05) ◽  
pp. 677-681
Author(s):  
Versha Rai ◽  
Muhammad Nadeem Chohan ◽  
Nazimuddin ◽  
Khuda Bux ◽  
Saadullah Chacher
Keyword(s):  
Controlled Trial ◽  
Persistent Asthma ◽  
Forced Expiratory Volume ◽  
P Value ◽  
Inhaled Corticosteroid ◽  
Inhaled Steroids ◽  
Group A ◽  
Duration Of Disease ◽  
Mild Persistent Asthma ◽  
Group B

Objective: To compare therapeutic response between Montelukast versus Montelukast plus inhaled corticosteroid (Budesonide) in children having mild persistent asthma. Study Design: Randomized Controlled Trial. Setting: Department of Pediatrics Medicine, National Institute of Child Health, Karachi. Period: 1st April 2016 to 30th September 2016. Material & Methods: Children aged 2 years to 14 years having mild persistent asthma for more than 6 months were included. After treatment Good response was considered when, forced expiratory volume in first second (FEV1) became >7.5% from baseline. Group A was given montelukast as monotherapy once daily and Group B was given Montelukast along with inhaled corticosteroid (Budesonide.  At 6 weeks followup change in FEV1 was recorded. Result: Mean age of the patients in montelukast alone (Group A) was 6.77+/-2.16 years while in montelukast with Inhaled Corticosteroid (Group B) was 6.97+/-2.17 years. Duration of disease in Group A was 18.32+/-6.12 months while in montelukast with ICS group was 18.50 +/-6.08 months. Baseline FEV1 in Group A was 81.83+/-0.85% while in Group B was 82.05 +/-0.63%. Males were higher with 131 (61.8%). Family history was positive in 82 (38.70%) patients. After 6 weeks mean FEV1 was 89.49 +/-0.87% in Group A while in Group B was 89.53+/-0.86%. Overall good responses were found in 21 (9.09%) patients. In Group A, good response was found in 5 (4.7%) patients while in Group B was in 16 (15.1%) with significant p-value. Conclusion: In our study montelukast along with inhaled steroids had better response than montelukast alone in mild persistent asthma.

scholarly journals Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Malgorzata Labuda ◽  
Sophie Laberge ◽  
Julie Brière ◽  
Denis Bérubé ◽  
Patrick Beaulieu ◽  
...  
Keyword(s):  
Genetic Variants ◽  
Symptom Relief ◽  
Forced Expiratory Volume ◽  
Airway Smooth Muscle Cells ◽  
Short Acting ◽  
Asthmatic Children ◽  
Controller Medication ◽  
Asthma Patients ◽  
Phosphodiesterase Type ◽  
Bronchodilator Responsiveness

Short-acting b2-adrenergic receptor agonists are commonly used bronchodilators for symptom relief in asthmatics. The aim of this study was to test whether genetic variants inPDE4Dgene, a key regulator of b2-adrenoceptor-induced cAMP turnover in airway smooth muscle cells, affect the response to short-acting b2-agonists. Bronchodilator responsiveness was assessed in 133 asthmatic children by % change in baseline forced expiratory volume in one second (FEV1) after administration of albuterol. The analyses were performed in patients with airway obstruction (FEV1/FVC ratio below 90%,n=93). FEV1  % change adjusted for baseline FEV1values was significantly different between genotypes of rs1544791 G/A polymorphism (P=0.006) and −1345 C/T (rs1504982) promoter variation (P=0.03). The association remained significant with inclusion of age, sex, atopy, and controller medication into multivariate model (P=0.004andP=0.02, resp.). Our work identifies new genetic variants implicated in modulation of asthma treatment, one of them (rs1544791) previously associated with asthma phenotype.

scholarly journals Budesonide-Formoterol as Needed for The Treatment of Mild Persistent Asthma

2021 ◽  
Vol 2 (2) ◽  
Author(s):  
Emily B. Walsh ◽  
Alicia B. Forinash ◽  
Rebecca L. Stauffer ◽  
Abigail Yancey ◽  
Erica F. Crannage ◽  
...  
Keyword(s):  
Low Dose ◽  
Data Extraction ◽  
Symptom Control ◽  
Asthma Management ◽  
Persistent Asthma ◽  
Global Strategy ◽  
Beta Agonist ◽  
Mild Asthma ◽  
Inhaled Corticosteroid ◽  
Mild Persistent Asthma

Objective: To summarize literature assessing the safety and efficacy of budesonide/formoterol, a low dose inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) used as needed for the treatment of adult patients with mild persistent asthma requiring step 2 therapy compared to low dose inhaled corticosteroid (ICS) plus short-acting beta agonist (SABA) and SABA monotherapy. Data Sources: A literature search of PubMed (1966-October 2020), EMBASE (1973-October 2020) and clinicaltrials.gov was conducted using the following search terms: budesonide, formoterol, as needed, and mild asthma. Study selection and data extraction: Randomized, controlled trials with data describing as needed use of budesonide-formoterol in the treatment of mild, persistent asthma were included. Data synthesis: Current trials demonstrate a reduced risk of exacerbation and an improvement in symptom control in patients receiving budesonide/formoterol as needed when compared to as needed SABA alone. However, when compared to scheduled budesonide maintenance, patients receiving budesonide/formoterol as needed experienced worse symptom control and mixed exacerbation results. Relevance to patient care and clinical practice: This review evaluates the efficacy and safety of budesonide/formoterol as needed for patients with mild asthma. The Global Initiative for Asthma (GINA), a global strategy for asthma management and prevention adopted this change in 2019, and the most recent updated Expert Panel Report 4 of the National Asthma Education and Prevention Program (NAEPP) did not address this area. Conclusions: Based on this review of the literature, further study is needed to determine the place in therapy for budesonide/formoterol as needed in the treatment of mild persistent asthma. Low-dose ICS should remain the standard of therapy in patients with mild asthma requiring Step 2 therapy.

scholarly journals Swimming and Persons with Mild Persistant Asthma

2007 ◽  
Vol 7 ◽  
pp. 1182-1188 ◽  
Author(s):  
Mirjana Arandelovic ◽  
Ivana Stankovic ◽  
Maja Nikolic
Keyword(s):  
Lung Function ◽  
Inhaled Corticosteroids ◽  
Bronchial Hyperresponsiveness ◽  
Persistent Asthma ◽  
Forced Expiratory Volume ◽  
Control Group ◽  
Significant Difference ◽  
Group A ◽  
Mild Persistent Asthma ◽  
Group B

The aim of our study was to analyze the effect of recreational swimming on lung function and bronchial hyperresponsiveness (BHR) in patients with mild persistent asthma. This study included 65 patients with mild persistent asthma, who were divided into two groups: experimental group A (n = 45) and control group B (n = 20). Patients from both groups were treated with low doses of inhaled corticosteroids (ICS) and short-acting β2 agonists salbutamol as needed. Our program for patients in group A was combined asthma education with swimming (twice a week on a 1-h basis for the following 6 months). At the end of the study, in Group A, we found a statistically significant increase of lung function parameters FEV1 (forced expiratory volume in 1 sec) (3.55 vs. 3.65) (p < 0.01), FVC (forced vital capacity) (4.27 vs. 4.37) (p < 0.05), PEF (peak expiratory flow) (7.08 vs. 7.46) (p < 0.01), and statistically significant decrease of BHR (PD200.58 vs. 2.01) (p < 0.001). In Group B, there was a statistically significant improvement of FEV1 3.29 vs. 3.33 (p < 0.05) and although FVC, FEV1/FVC, and PEF were improved, it was not significant. When Groups A and B were compared at the end of the study, there was a statistically significant difference of FVC (4.01 vs. 4.37), FEV1 (3.33 vs. 3.55), PEF (6.79 vs.7.46), and variability (p <0.001), and statistically significantly decreased BHR in Group A (2.01 vs. 1.75) (p < 0.001). Engagement of patients with mild persistent asthma in recreational swimming in nonchlorinated pools, combined with regular medical treatment and education, leads to better improvement of their parameters of lung function and also to more significant decrease of their airway hyperresponsiveness compared to patients treated with traditional medicine

Sign in / Sign up

Export Citation Format

Share Document